Potential immunosuppressive effects of TGF-β are accepted in autoimmune diseases used against most immune cells through the development and peripheral differentiation of Tregs and induced expression of FOXP3 in the context of T1D [67, 72]. This evidence concerns the gene TGFB1 and type 1 diabetes mellitus.